Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Preferred Shares (2023 - 2026)

SAB Biotherapeutics filings provide 4 years of Preferred Shares readings, the most recent being $59.0 for Q1 2026.

  • On a quarterly basis, Preferred Shares rose 1080.0% to $59.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $59.0, a 1080.0% increase, with the full-year FY2025 number at $3.0, down 40.0% from a year prior.
  • Preferred Shares hit $59.0 in Q1 2026 for SAB Biotherapeutics, up from $3.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $59.0 in Q1 2026 to a low of $3.0 in Q3 2025.
  • Median Preferred Shares over the past 4 years was $5.0 (2023), compared with a mean of $10.0.
  • Biggest five-year swings in Preferred Shares: tumbled 40.0% in 2025 and later skyrocketed 1080.0% in 2026.
  • SAB Biotherapeutics' Preferred Shares stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then tumbled by 40.0% to $3.0 in 2025, then surged by 1866.67% to $59.0 in 2026.
  • The last three reported values for Preferred Shares were $59.0 (Q1 2026), $3.0 (Q4 2025), and $3.0 (Q3 2025) per Business Quant data.